Vivus: Consensus Calls For FDA Approval, But Watch For Label Restrictions
Research - PREVIEW: The Prescription Drug User Fee Act (PDUFA) or FDA ‘Action’ date for Vivus’ (NASDAQ:VVUS) obesity drug, Qnexa, is July 17th – an event that’s … Continue Reading
Read now